Cargando…

Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use

Detalles Bibliográficos
Autor principal:	Scott, Lesley J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325092/ https://www.ncbi.nlm.nih.gov/pubmed/31186615 http://dx.doi.org/10.1007/s40267-018-0594-z

Ejemplares similares

Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
por: Scott, Lesley J.
Publicado: (2018)

Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

Correction to: Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
por: Ohe, Yuichiro, et al.
Publicado: (2018)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
por: Cheng, Ying, et al.
Publicado: (2021)

Correction to: Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report
por: Wang, Musen, et al.
Publicado: (2021)

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
por: Lamb, Yvette N.
Publicado: (2021)

A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
por: Chihara, Yusuke, et al.
Publicado: (2022)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Correction: Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report
por: Patel, Karishma, et al.
Publicado: (2023)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
por: Denis, Marc G, et al.
Publicado: (2020)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
por: Volta, Francesco, et al.
Publicado: (2023)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Effect of the First-Line Therapy with Osimertinib for a Metastatic Choroidal Tumor in Advanced-Stage Lung Cancer: A Case Report
por: Umeda, Ikuko, et al.
Publicado: (2023)

Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC
por: Cekay, Michael, et al.
Publicado: (2023)

Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
por: Meraz, Ismail M., et al.
Publicado: (2023)

Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib
por: Fan, WuQiang, et al.
Publicado: (2019)

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2022)

Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
por: OuYang, Pu-Yun, et al.
Publicado: (2013)

Correction to: Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment
por: Jarry, Ulrich, et al.
Publicado: (2021)

Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
por: Yi, Yali, et al.
Publicado: (2022)

Correction to: Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
por: Zhao, Yuanyang, et al.
Publicado: (2021)

Correction to targeting the EMT transcription factor snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer
Publicado: (2023)

Correction to: Anakinra in Still’s disease: a profile of its use
por: Lyseng‑Williamson, Katherine A.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aip55e1nunkdsv028h3p9cod64